Status:
COMPLETED
Endodontic Medications for Irreversible Pulpitis: Articaine or Eugenol?
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Pulpitides
Endodontic Inflammation
Eligibility:
All Genders
18+ years
Brief Summary
The objective of the study is to determine which of the two commonly used endodontic medications (Eugenol VS Articaine) is most effective in controlling postoperative pain in irreversible pulpitis of ...
Detailed Description
In irreversible pulpitis of the mature permanent tooth, the enrolled patients receive endodontic medications (Eugenol or Articaine) in order to determine which one is the more efficient to control the...
Eligibility Criteria
Inclusion
- Adult patient, major, affiliated to a social health insurance scheme
- Patient having agreed to participate in the study
- Urgent consultant patient for irreversible pulpitis
- Patient understanding French
Exclusion
- Refusal of the patient to participate in the study
- Impossibility of performing the surgical procedure
- Impossibility to give the subject information enlightened (difficulty of understanding ...)
- Subject under the protection of justice, or under guardianship
- General contraindication to endodontic treatment in 2 sessions (high risk of infectious endocarditis, for example)
- Chronic intake of analgesic drugs
Key Trial Info
Start Date :
March 22 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 24 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03472456
Start Date
March 22 2018
End Date
October 24 2019
Last Update
September 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Les Hôpitaux Universitaires de Strasbourg
Strasbourg, France, 67091